

Guideline #	Guideline Name	Type of Change	Brief Description of Guideline Change	Reason for Changes
NEW	Lifyorli (relacorilant)	Positive	On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.	New FDA Drug/Indication
ECG 3077	Evolut Clinical Guideline 3077 for Iron Products	No clinical change	Updated references	Annual Review
ECG 3078	Evolut Clinical Guideline 3078 for Torisel (temsirolimus)	No clinical change	Updated references	Annual Review
ECG 3079	Evolut Clinical Guideline 3079 for Zelboraf (vemurafenib)	No clinical change	Updated references	Annual Review
ECG 3080	Evolut Clinical Guideline 3080 for Doxil (liposomal doxorubicin)	No clinical change	Updated references	Annual Review
ECG 3103	Evolut Clinical Guideline 3103 for Cometriq/Cabometyx (cabozantinib)	No clinical change	Updated references	Annual Review
ECG 3081	Evolut Clinical Guideline 3081 for Mekinist (trametinib)	No clinical change	1) Added oral solution formulation details to exclusion criteria 2) Updated references	Annual Review
ECG 3082	Evolut Clinical Guideline 3082 for Tafinlar (dabrafenib)	No clinical change	1) Added tablet formulation details to exclusion criteria 2) Updated references	Annual Review
ECG 3083	Evolut Clinical Guideline 3083 for Imbruvica (ibrutinib)	No clinical change	1) Added oral suspension formulation details to exclusion criteria 2) Updated references	Annual Review
ECG 3084	Evolut Clinical Guideline 3084 for Zydelig (idelalisib)	No clinical change	Updated references	Annual Review
ECG 3085	Evolut Clinical Guideline 3085 for Alecensa (alecetinib)	No clinical change	1) Updated indication section 2) Updated exclusion criteria 3) Updated references	Annual Review
ECG 3086	Evolut Clinical Guideline 3086 for Cotellic (cobimetinib)	No clinical change	1) Updated exclusion criteria 2) Updated references	Annual Review
ECG 3087	Evolut Clinical Guideline 3087 for Bavencio (avelumab)	No clinical change	Updated references	Annual Review
ECG 3088	Evolut Clinical Guideline 3088 for Alunbrig (brigatinib)	No clinical change	Updated references	Annual Review
ECG 3089	Evolut Clinical Guideline 3089 for Rydapt (midostaurin)	No clinical change	Updated references	Annual Review
ECG 3090	Evolut Clinical Guideline 3090 for Elzonris (tagraxofusp)	No clinical change	Updated references	Annual Review
ECG 3091	Evolut Clinical Guideline 3091 for Turalio (pexidartinib)	No clinical change	Updated references	Annual Review
ECG 3092	Evolut Clinical Guideline 3092 for Inrebic (fedratinib)	No clinical change	Updated references	Annual Review
ECG 3094	Evolut Clinical Guideline 3094 for Ultomiris (ravulizumab)	No clinical change	Updated references	Annual Review
ECG 3095	Evolut Clinical Guideline 3095 for Elitek (rasburicase)	No clinical change	Updated references	Annual Review
ECG 3096	Evolut Clinical Guideline 3096 for Qinlock (ripretinib)	No clinical change	Updated references	Annual Review
ECG 3097	Evolut Clinical Guideline 3097 for Abecma (idecabtagene vicleuce)	Positive	1) Removed REMS requirement under "Contraindications/Warnings" section 2) Updated maximum dose to "510 x 106 CAR-positive T cells" under exclusion criteria 3) Updated references	Annual Review
ECG 3098	Evolut Clinical Guideline 3098 for Empaveli (pegcetacoplan)	No clinical change	Updated references	Annual Review
ECG 3100	Evolut Clinical Guideline 3100 for Pyrukynd (mitapivat)	No clinical change	Updated references	Annual Review
ECG 3102	Evolut Clinical Guideline 3102 for Voydeya (danicopan)	No clinical change	1) Updated exclusion criteria 2) Updated references	Annual Review
ECG 3104	Evolut Clinical Guideline 3104 for Radiopharmaceuticals	Positive	1) Added total number of doses for Lutathera (lutetium Lu 177 dotatate) under exclusion criteria 2) Updated exclusion criteria details for Zevalin (ibritumomab tiuxetan) 3) Updated references	Annual Review
ECG 3108	Evolut Clinical Guideline 3108 for Unloxcyt (cosibelimab-ipdl)	No clinical change	1) Updated exclusion criteria 2) Updated references	Annual Review
ECG 3107	Evolut Clinical Guideline 3107 for Ziihera (zanidatamab-hrii)	No clinical change	1) Updated exclusion criteria 2) Updated references	Annual Review
ECG 3074	Bone Modifying Agents	Positive	On March 30, 2026, the Food and Drug Administration approved Ponlimsi (denosumab-adet), a biosimilar to Prolia (denosumab). 1) Added new biosimilar to policy 2) Updated HCPC codes 3) Updated references	Other
ECG 3013	Libtayo (cemiplimab-rwlc)	Positive	1) Updated maximum dose to "700 mg" under exclusion criteria 2) Updated references	Other
ECG 3039	Generic Drugs	Positive	1) Added "Gliadel Wafer (carmustine implant)" to the drug list in Attachment A 2) Updated references	Other
ECG 3109	Intravenous Immune Globulin (IG)	Positive	Updated HCPC code for "Yimmugo"	Other

ECG 3129	Ojemda (tovorafenib)	Positive	1) Added oral suspension formulation details to exclusion criteria 2) Updated references	Other
ECG 3258	Blincyto (blinatumomab)	Positive	1) Updated indication section to include: - Use as induction therapy, and - Combination therapy use in R/R setting 2) Updated references	Other
ECG 3264	Antiemetics	Positive	1) Added "Focinvez (fosaprepitant injection)" to all relevant sections 2) Updated references	Other